Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.

Parienti JJ, Massari V, Rey D, Poubeau P, Verdon R.

Clin Infect Dis. 2007 Jul 15;45(2):263-6. doi: 10.1086/518973. Epub 2007 Jun 6.

Many antiretroviral therapies, including efavirenz, are associated with increased serum concentrations of low-density lipoprotein cholesterol. In a small 52-week randomized study, we found that switching from efavirenz to nevirapine was associated with significantly decreased low-density lipoprotein cholesterol levels, compared with continuation of efavirenz therapy (P<.04). A switch to nevirapine was associated with no severe adverse events.

PMID: 17578790

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.